Population data | Â |
---|---|
11-years old women cohort (2012) | 123,581 [18] |
Screening characteristics[19] | Â |
Regular screening coverage | 57.0% [20] |
Interval between regular screening | 3Â years [10] |
Irregular screening coverage | 0.0% |
Population without screening | 43.0% [20] |
Age of initiation of screening | 25Â years [10] |
Sensitivity to detect CIN1 | 58.0% [10] |
Sensitivity to detect CIN2 and CIN3 | 61.0% [10] |
Estimated positive Pap smear | 1.7% [10] |
Treatment performance[21] | Â |
CIN1 detected by the screening and undergoing treatment a | 40.0% [22] |
Efficacy of CIN1 treatment a | 100.0% [10] |
CIN1 treatment effectiveness b | 40.0% |
CIN2 and CIN3 detected by the screening and undergoing treatment a | 100.0% [10] |
Efficacy of CIN 2 and 3 treatment a | 90.0% [10] |
CIN2 and CIN3 treatment effectiveness b | 90.0% |
Five-year cancer cure rate | 64.0% [1] |
Parameters to estimate vaccine effectiveness | Â |
Prevalence of HPV types 16 and 18 in cervical cancer | 80.0% [23] |
Prevalence of other oncogenic HPV in cervical cancer | 20.0% [23] |
Prevalence of HPV types 16 and 18 in CIN23 | 46.5% [19] |
Prevalence of other oncogenic HPV in CIN23 | 29.8% [19] |
Prevalence of HPV types 16 and 18 in CIN1 | 36.5% [19] |
Prevalence of other oncogenic HPV in CIN1 | 42.9% [19] |
Prevalence of HPV types 6 and 11 in CIN1 | 15.8% [19] |
Prevalence of HPV types 6 and 11 in GW | 76.2% [24] |
Vaccine efficacy to HPV types16 and 18 CC (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to HPV types16 and 18 CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to HPV types16 and 18 CIN1 (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to other oncogenic HPV CC (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to other oncogenic HPV CIN23 (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to other oncogenic HPV CIN1 (HPV-16/18 & HPV-6/11/16/18 vaccines) | |
Vaccine efficacy to HPV types 6 and 11 for HPV-6/11/16/18 vaccine | |
Costs[35] | US dollars |
Pap smear cost (including false positive tests) | 26.19 |
GW treatment | 62.00 |
CIN1 treatment & follow-up cost | 1,636.00 |
CIN2 and CIN3 treatment & follow-up cost | 1,636.00 |
Cervical cancer treatment | 13,218.00 |
Cost per vaccinated woman (price parity between vaccines) c | 60.00 |